[Summary of the recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) on the therapeutic drug monitoring of tacrolimus].
暂无分享,去创建一个
[1] U. Christians,et al. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report , 2019, Therapeutic drug monitoring.
[2] S. Chadban,et al. Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. , 2018, Journal of the American Society of Nephrology : JASN.
[3] K. Boudjema,et al. High Intrapatient Variability of Tacrolimus Exposure in the Early Period After Liver Transplantation Is Associated With Poorer Outcomes , 2018, Transplantation.
[4] D. D. de Lange,et al. Association of Whole Blood Tacrolimus Concentrations with Kidney Injury in Heart Transplantation Patients , 2017, European Journal of Drug Metabolism and Pharmacokinetics.
[5] S. Bremer,et al. NFAT‐regulated cytokine gene expression during tacrolimus therapy early after renal transplantation , 2017, British journal of clinical pharmacology.
[6] L. Rostaing,et al. Reduction of Extended‐Release Tacrolimus Dose in Low‐Immunological‐Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor‐Specific Antibodies: A Randomized Study , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[7] M. Loriot,et al. Pharmacogenetics of immunosuppressants: State of the art and clinical implementation - recommendations from the French National Network of Pharmacogenetics (RNPGx). , 2017, Therapie.
[8] J. Meulenbelt,et al. High tacrolimus blood concentrations early after lung transplantation and the risk of kidney injury , 2017, European Journal of Clinical Pharmacology.
[9] J. Pascual,et al. Should IFN-γ, IL-17 and IL-2 be considered predictive biomarkers of acute rejection in liver and kidney transplant? Results of a multicentric study. , 2014, Clinical immunology.
[10] T. Giese,et al. Reduced residual gene expression of nuclear factor of activated T cells‐regulated genes correlates with the risk of cytomegalovirus infection after liver transplantation , 2014, Transplant infectious disease : an official journal of the Transplantation Society.
[11] A. Rimola,et al. Intracellular IFN-γ and IL-2 expression monitoring as surrogate markers of the risk of acute rejection and personal drug response in de novo liver transplant recipients. , 2013, Cytokine.
[12] A. Burroughs,et al. Tacrolimus Trough Levels, Rejection and Renal Impairment in Liver Transplantation: A Systematic Review and Meta‐Analysis , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[13] T. Giese,et al. Pharmacodynamic Monitoring of Cyclosporin A Reveals Risk of Opportunistic Infections and Malignancies in Renal Transplant Recipients 65 Years and Older , 2011, Therapeutic drug monitoring.
[14] A. Sánchez‐Fueyo,et al. Biomarkers of immunoregulatory status in stable liver transplant recipients undergoing weaning of immunosuppressive therapy. , 2010, Clinical immunology.
[15] T. Giese,et al. Individualized Monitoring of Nuclear Factor of Activated T Cells-Regulated Gene Expression in FK506-Treated Kidney Transplant Recipients , 2010, Transplantation.
[16] K. Terasako,et al. Target blood concentrations of CYA and tacrolimus in randomized controlled trials for the prevention of acute GVHD after hematopoietic SCT , 2010, Bone Marrow Transplantation.
[17] O. Shpilberg,et al. Prophylaxis regimens for GVHD: systematic review and meta-analysis , 2009, Bone Marrow Transplantation.
[18] V. Haufroid,et al. Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference , 2009, Therapeutic drug monitoring.
[19] P. Halloran,et al. Reduced exposure to calcineurin inhibitors in renal transplantation. , 2007, The New England journal of medicine.
[20] B. Maes,et al. Clinical Efficacy and Toxicity Profile of Tacrolimus and Mycophenolic Acid in Relation to Combined Long‐term Pharmacokinetics in de Novo Renal Allograft Recipients , 2004, Clinical pharmacology and therapeutics.
[21] H. Dohy,et al. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation , 2001, Bone Marrow Transplantation.
[22] B. Meiser,et al. Suggested guidelines for the use of tacrolimus in cardiac transplant recipients. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[23] L. Shaw,et al. Clinical Utility of Monitoring Tacrolimus Blood Concentrations in Liver Transplant Patients , 2001, Journal of clinical pharmacology.
[24] J. Fay,et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. , 2000, Blood.
[25] J. Hooff,et al. Low systemic exposure to tacrolimus correlates with acute rejection. , 1999, Transplantation proceedings.